Non-cardiogenic ischemic stroke in acute phase.
Conditions
Interventions
Aspirin and cilostazol group Aspirin (100mg/day) and cilostazol (200mg/day) are administered for 3months.
Aspirin group Aspirin (100mg/day) is administered for 3months.
Sponsors
Department of Neurosurgery, Faculty of Medicine, University of Tsukuba
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) The diagnosis of ischemic stroke was based on neurological examination and computed tomography or magnetic resonance imaging. 2) Being able to taking drugs orally. 3) An age of 20 years or older, with written informed consent.
Exclusion criteria
Exclusion criteria: 1) Having aphasia or mental retardation. 2) Having serious liver dysfunction, renal dysfunction, angina, myocardial infarction. 3) Having hemorrhagic disease. 4) Having tachyarrhythmia to need treatment. 5) A patient with suspected cardiogenic cerebral infarction. 6) Contraindication for cilostazol, aspirin, ozagrel, and edaravon.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of patients with mRS 0 to 3 at 3 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) The frequency of progressive stroke on day 2 and7. 2) The frequency of stroke and myocardial infarction. 3) The frequency of hemorrhagic event. 4) The frequency of adverse event. | — |
Countries
Japan
Contacts
Public ContactYasunobu Nakai
Faculty of Medicine, University of Tsukuba Department of Neurosurgery
Outcome results
None listed